Top Stories
A smart phone on a desk with Anthropic's Claude logo on the screen

Anthropic confidentially files for IPO: Here's what it means

Anthropic announced today that it had " confidentially submitted a draft registration statement on Form S-1 to the U.S. Securities and Exchange Commission for a proposed initial public offering of our common stock." An S-1 is the registration document a company files with regulators before it

A picture inside an empty theatre in Netflix's Tokyo office with Netflix logo on the screen

Netflix Stock Price Soars After Earnings Report Record New Memberships

Netflix stock price ( NASDAQ: NFLX ) is up more than 13% in the after-hours following its release of the fourth-quarter earnings report for fiscal year 2024. The streaming company recorded a 16% increase in revenue year-over-year, reaching 19% on a foreign exchange (F/X) neutral basis, which the

Latest News

Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing

GlobeNewswire Inc.

LITTLETON, Colo., June 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associ

Prestige Consumer Healthcare Inc. to Participate in the Oppenheimer Annual Consumer Growth and E-Commerce Conference

GlobeNewswire Inc.

TARRYTOWN, N.Y., June 05, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will participate in a fireside chat at the Oppenheimer 26th Annual Consumer Growth and E-Commerce Conference virtually on Monday,

DiagnosTear Achieves Major Scientific Milestone with Publication of TeaRx(TM) Clinical Study in Current Eye Research Journal

Newsfile

Publication in a leading peer-reviewed ophthalmology journal further validates TeaRx™ as a novel point-of-care platform for diagnosis, patient stratification, and prediction of responsiveness to therapy in Dry Eye Disease https://pubmed.ncbi.nlm.nih.

Nuwellis Announces Pricing of $6 Million Public Offering

GlobeNewswire Inc.

MINNEAPOLIS, June 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announces the pricing of a public offering of 20,000,000 shar

Blink Charging Announces Strategic Sale of Envoy to Blade Ranger to Advance Focus on Core Charging Infrastructure

GlobeNewswire Inc.

Transaction underscores shift to a focused, operator-led model centered on reliability, utilization, and financial performance Bowie, MD, June 05, 2026 (GLOBE NEWSWIRE) -- Blink Charging Co. (NASDAQ: BLNK) (“Blink” or the “Company”), a leading global

EVA Live launches FastQuoteDirect, it’s AI-Powered Consumer Engagement Platform Across 5.6 Billion Dollar Market

GlobeNewswire Inc.

LOS ANGELES, CA, June 05, 2026 (GLOBE NEWSWIRE) -- EVA Live, Inc. (NASDAQ: GOAI) EVA Live Product Update: FastQuoteDirect.com (FQD) is pleased to announce the deployment of its next-generation AI-powered customer engagement platform, powered by EVA L

Protium Clean Energy Corp. Enters Agreement to Acquire Emma and Ten O'Clock Property

Newsfile

Toronto, Ontario--(Newsfile Corp. - June 5, 2026) - Protium Clean Energy Corp. (CSE: GRUV) (the "Company") announces that it has entered into a property purchase and sale agreement (the "Acquisition Agreement") with the beneficial owners (the "Seller

Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision Radionuclide Therapy™

GlobeNewswire Inc.

Kennewick, WA, June 05, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a company pioneering Precision Radionuclide Therapy™ (PRnT) with its innovative RadioGel® technology, today announced the submission of its Early Feasibility IDE application t

Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML

GlobeNewswire Inc.

Surveyed oncologists reported high likelihood to prescribe (6 of 7), citing deep remissions, transplant-bridging potential, biomarker-agnostic use and reduced cardiotoxicity as key drivers Parallel survey of payers shows strong support for Annamycin

Ocean Power Technologies Announces Pricing of $10,000,000 Registered Direct Offering Priced At A Premium to Market

GlobeNewswire Inc.

MONROE TOWNSHIP, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- Ocean Power Technologies, Inc. (NYSE American: OPTT) (“OPT” or the “Company”), today announced that it has entered into securities purchase agreements with certain institutional investors for t